Etanercept 50mg (DrugBank: Etanercept)
15 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
15 | Inclusion body myositis | 0 |
28 | Systemic amyloidosis | 0 |
35 | Pemphigus | 0 |
38 | Stevens-Johnson syndrome | 0 |
39 | Toxic epidermal necrolysis | 0 |
46 | Malignant rheumatoid arthritis | 1 |
50 | Dermatomyositis | 0 |
53 | Sjogren syndrome | 0 |
56 | Behcet disease | 0 |
60 | Aplastic anemia | 0 |
85 | Idiopathic interstitial pneumonia | 0 |
228 | Bronchiolitis obliterans | 0 |
271 | Ankylosing spondylitis | 0 |
285 | Fanconi anemia | 0 |
298 | Hereditary pancreatitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000008572 | 2012/07/31 | 31/07/2012 | The Kitasato institute Non-inferiorty trial of Etanercept and Tacrolimus ,the combined therapy with Methotrexate in rhumatoid arthritis patients | Rheumatoid arthritis (RA) with inadequate response to methotrexate (MTX) | Tacrolimus group patients receive daily the optimal dosage of tacrolimus within the range between 1.5-3.0 mg/day for 52 weeks. Etanercept group patient receive weekly subcutaneous injection of etanercept 50mg for 52 weeks. | Department of Rheumatology and infectious disease, Kitasato university school of medicine | 1)Kitasato institute medical center hospital2)Kitasato institute hospital3)Ishikawa internal medicine clinic | Recruiting | 20years-old | 70years-old | Male and Female | 80 | Not applicable | Japan |